HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New Screener Features: See news and add color-coded flags

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Fractyl Health, Inc.

Contributing Author

Recent Articles by Fractyl Health, Inc.

3 hours
Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026 GUTS GlobeNewswire
Feb-26
Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita for Post-GLP-1 Weight Maintenance GUTS -6.19% GlobeNewswire
Jan-29
Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita After GLP-1 Discontinuation GUTS -68.04% GlobeNewswire
Jan-06
Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness GUTS GlobeNewswire
Jan-05
Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category GUTS -8.44% GlobeNewswire
Dec-15
Fractyl Health Announces Call of Tranche A Warrants Tied to August 2025 Public Offering Following Achievement of Clinical and Trading Milestones GUTS GlobeNewswire
Dec-02
Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita Procedure GUTS +17.95% GlobeNewswire
Dec-01
Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference GUTS GlobeNewswire
Nov-12
Fractyl Health Reports Third Quarter 2025 Results; Revita Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027 GUTS GlobeNewswire
Nov-05
Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025 GUTS GlobeNewswire
Oct-07
Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity GUTS -6.80% GlobeNewswire
Sep-26
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock GUTS +32.67% GlobeNewswire
Sep-26
Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita Maintained Weight Loss After GLP-1 Discontinuation GUTS +32.67% GlobeNewswire
Sep-03
Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth GUTS GlobeNewswire
Aug-12
Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates GUTS GlobeNewswire
Aug-07
Fractyl Health Announces Closing of $23 Million Underwritten Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares GUTS GlobeNewswire
Aug-06
Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference GUTS -45.99% GlobeNewswire
Aug-06
Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering GUTS -45.99% GlobeNewswire
Aug-05
Fractyl Health Announces Proposed Public Offering GUTS GlobeNewswire
Aug-05
Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure GUTS -45.99% GUTS GlobeNewswire
Jun-23
Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy GUTS -24.77% GlobeNewswire
Jun-23
Fractyl Health Presents New Data at the American Diabetes Association's 85th Scientific Sessions Demonstrating its Rejuva Smart GLP-1 Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models GUTS -24.77% GlobeNewswire
Jun-18
Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing GUTS GlobeNewswire
Jun-13
Fractyl Health to Present New Preclinical Data from its Rejuva Smart GLP-1 Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions GUTS -5.07% GlobeNewswire
Jun-04
Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita Across its Bariatric and Metabolic Endoscopy Centers Nationwide GUTS GlobeNewswire
May-19
Fractyl Health Advances Rejuva Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes GUTS +25.44% GlobeNewswire
May-17
Fractyl Health Unveils New Rejuva Smart GLP-1 Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025 GUTS GlobeNewswire
May-13
Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates GUTS -13.28% GUTS GlobeNewswire
May-06
Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference GUTS -7.98% GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)